Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis (STELLAR-2)
A Randomized, Double-Blind, Parallel Group, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
Sponsor: Biocon Biologics UK Ltd
This PHASE3 trial investigates Moderate to Severe Chronic Plaque Psoriasis and is currently completed. Biocon Biologics UK Ltd leads this study, which shows 10 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Oct 2025 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE3
▶ Show 5 earlier versions
-
Jun 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Jun 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE3
-
May 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Biocon Biologics UK Ltd
For direct contact, visit the study record on ClinicalTrials.gov .